Presentation is loading. Please wait.

Presentation is loading. Please wait.

Piotr Kuna, MD, Jadwiga Kaczmarek, MD, Maciej Kupczyk, MD 

Published bySusanti Wibowo Modified over 5 years ago

Similar presentations

Presentation on theme: "Piotr Kuna, MD, Jadwiga Kaczmarek, MD, Maciej Kupczyk, MD "— Presentation transcript:

1 Efficacy and safety of immunotherapy for allergies to Alternaria alternata in children 
Piotr Kuna, MD, Jadwiga Kaczmarek, MD, Maciej Kupczyk, MD  Journal of Allergy and Clinical Immunology  Volume 127, Issue 2, Pages e6 (February 2011) DOI: /j.jaci Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Fig 1 Study flow chart. QoL, Quality of life.
Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3 Fig 2 A alternata spore count (spores/m3) during baseline year (2003) and 3 consecutive years (2004, 2005, and 2006) of immunotherapy. Dashed horizontal line indicates the concentration necessary to induce symptoms (100 spores/m3). Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4 Fig 3 The weekly average of SMS recorded by patients daily during the season (July, August, and September) at baseline and after 3 consecutive years of immunotherapy (P = .73, .102, <.0001, and <.0001 for baseline, 1, 2, and 3 years of SIT, respectively, active therapy vs placebo, 1-way ANOVA test). The percent reductions, compared with placebo (calculated as area under the curve, [active - placebo]/placebo), were 10.8%, 38.7%, and 63.5% after first, second, and third years of SIT, respectively. Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5 Fig 4 Medication score (daily mean ± SEM) at baseline and after consecutive years of immunotherapy (Mann-Whitney U test, active therapy vs placebo). NS, Not significant. Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

6 Fig 5 Baseline and 4-year symptom scores (individual values, mean ± SEM, described by patients with the use of VAS; see details in the Methods section in this article’s Online Repository) after A alternata nasal challenge in groups given active therapy or placebo (P = .04 for active vs placebo; Mann-Whitney U test). Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

7 Average asthma (A), rhinitis (B), and conjunctivitis (C) SS (mean ± SEM) recorded by patients with VAS during the season (July, August, and September) at baseline and after consecutive years of immunotherapy (Mann-Whitney U test, active vs placebo). NS, Not significant. Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

8 QoL (mean ± SEM of scores, Juniper questionnaires) of patients with asthma (A) and rhinoconjunctivitis (B) at baseline and after consecutive years of immunotherapy (∗P < .05, active vs placebo, Mann-Whitney U test). Increase of score in the asthma questionnaire mirrors improvement in QoL, whereas in the rhinoconjunctivitis questionnaire, the situation is the opposite. Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Download ppt "Piotr Kuna, MD, Jadwiga Kaczmarek, MD, Maciej Kupczyk, MD "

Similar presentations

Clinical trial design, nasal allergen challenge models, and considerations of relevance to pediatrics, nasal polyposis, and different classes of medication 

Clinical trial design, nasal allergen challenge models, and considerations of relevance to pediatrics, nasal polyposis, and different classes of medication 
Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy  Monica B. Arvidsson, MD, Olle.

Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy  Monica B. Arvidsson, MD, Olle.
Efficacy and safety of birch pollen immunotherapy for local allergic rhinitis  Andrzej Bożek, MD, PhD, Krzysztof Kołodziejczyk, MD, PhD, Jerzy Jarząb,

Efficacy and safety of birch pollen immunotherapy for local allergic rhinitis  Andrzej Bożek, MD, PhD, Krzysztof Kołodziejczyk, MD, PhD, Jerzy Jarząb,
Allergen immunotherapy: A practice parameter third update

Allergen immunotherapy: A practice parameter third update
Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses  Stephen R. Durham,

Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses  Stephen R. Durham,
Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo  Eli O. Meltzer, MD, Claus Bachert,

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo  Eli O. Meltzer, MD, Claus Bachert,
Effects of time, albuterol, and budesonide on the shape of the flow-volume loop in children with asthma  Anand C. Patel, MD, Mark L. Van Natta, MHS, James.

Effects of time, albuterol, and budesonide on the shape of the flow-volume loop in children with asthma  Anand C. Patel, MD, Mark L. Van Natta, MHS, James.
Petasol butenoate complex (Ze 339) relieves allergic rhinitis–induced nasal obstruction more effectively than desloratadine  Alina F. Dumitru, MD, Mohamed.

Petasol butenoate complex (Ze 339) relieves allergic rhinitis–induced nasal obstruction more effectively than desloratadine  Alina F. Dumitru, MD, Mohamed.
Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses  Stephen R. Durham,

Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses  Stephen R. Durham,
Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5– grass pollen tablet for seasonal allergic rhinitis  Alain Didier, MD,

Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5– grass pollen tablet for seasonal allergic rhinitis  Alain Didier, MD,
Jay A. Lieberman, MD, Faith R. Huang, MD, Hugh A

Jay A. Lieberman, MD, Faith R. Huang, MD, Hugh A
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Montelukast treatment may alter the early efficacy of immunotherapy in children with asthma  Paweł Majak, MD, PhD, Błażej Rychlik, PhD, Łukasz Pułaski,

Montelukast treatment may alter the early efficacy of immunotherapy in children with asthma  Paweł Majak, MD, PhD, Błażej Rychlik, PhD, Łukasz Pułaski,
Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,
Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults  Peter S. Creticos, MD, Jennifer Maloney,

Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults  Peter S. Creticos, MD, Jennifer Maloney,
Epicutaneous allergen-specific immunotherapy ameliorates grass pollen–induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation.

Epicutaneous allergen-specific immunotherapy ameliorates grass pollen–induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation.
Epidemic asthma and the role of the fungal mold Alternaria alternata

Epidemic asthma and the role of the fungal mold Alternaria alternata
Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 

Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 
Incident asthma and Mycoplasma pneumoniae: A nationwide cohort study

Incident asthma and Mycoplasma pneumoniae: A nationwide cohort study
Preventive effect of nasal filters on allergic rhinitis: A randomized, double-blind, placebo- controlled crossover park study  Peter Kenney, BSc, Ole Hilberg,

Preventive effect of nasal filters on allergic rhinitis: A randomized, double-blind, placebo- controlled crossover park study  Peter Kenney, BSc, Ole Hilberg,

Similar presentations

Ads by Google